TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02454049

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: beetroot juice
Description: 6mmol nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: sodium nitrate
Description: 6mmol sodium nitrate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: water
Description: plain water
Study: NCT03020069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGMS Device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Device
Study: NCT00238953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study: NCT00709501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disseminating Effective Habits for Long-term Weight Loss
Description: Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Achieve Together website
Description: access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
Study: NCT00950196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amantadine sulphate
Description: amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
Study: NCT00262002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY PS (MenACWY-CRM, polysaccharide vaccine)
Description: MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV (Hepatitis B vaccine)
Description: Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
Study: NCT01615172

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cannulation
Description: The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cannulation
Description: The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
Study: NCT03099408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole Oral
Description: Oral metronidazole 400 mg BID for 7 days at first month.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole and Lactobacillus
Description: Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
Study: NCT00600847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose for 7 days, oral, 20mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desloratadine
Description: single dose for 7 days, oral, 5 mg
Study: NCT00262002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV (Hepatitis B vaccine)
Description: Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
Study: NCT00600847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: single dose for 7 days, oral
Study: NCT01630005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: talk therapy
Description: Psychotherapy
Study: NCT00262002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HBV (Hepatitis B vaccine)
Description: Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)
Description: Prevnar was administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)
Description: Prevnar was administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)
Description: Prevnar was administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR (Measles, Mumps and Rubella vaccine)
Description: MMR at 12 month of age, administered in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR (Measles, Mumps and Rubella vaccine)
Description: MMR at 12 month of age, administered in the left arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
Study: NCT01045863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 Cohort 1
Description: First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
Study: NCT00262002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)
Description: DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menjugate (Men C conjugated vaccine)
Description: Menjugate was injected IM in the anterolateral area of the right thigh.
Study: NCT00927225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%, 50 mL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Study: NCT01017757

Intervention type: PROCEDURE
Intervention: High-resolution CT scanning
Description: High-resolution CT scanning
Study: NCT03039608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）
Description: local steroid injection and oral steroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral steroid administration（prednisone）
Description: oral steroid
Study: NCT01181947

Intervention type: DEVICE
Intervention: TEVAR
Description: Thoracic endovascular aneurysm repair
Study: NCT01045863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792 Cohort 2
Description: Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03382792
Description: Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food Effect cohort
Description: Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSF cohort
Description: Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
Study: NCT02968823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Licorice
Description: ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar water
Description: Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 3
Study: NCT02713971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamepad system
Description: Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
Study: NCT03765398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR Cognitive-motor-balance training
Description: The participant will play four of the six balance board games Table tilt, Tightrope, Soccer, Balance bubble, Light Run and Basic Step (each game is max 1.5 minutes). Each game will be superimposed with any 3 of the 6 cognitive tasks (word list generation consisting of verbal fluency (VF) and category fluency (CF), digit recall (DR), analogies (AN), mental arithmetic (MA), repeated letter (RL). The cognitive tasks will be randomized making sure that all the cognitive tasks are played with all the games. The cognitive and balance board game scores will be noted on the scoring sheet for each session. A total 10 minutes rest interval between every sub-session will be mandatorily provided.
Study: NCT01382498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium dobesilate (Doxium)
Description: 500 mg, Tablet, Daily, 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: Similar to the that of the Experimental arm, Daily, Three months
Study: NCT03232710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosiqing
Description: Aripiprazole Orally disintegrating tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosiqing
Description: Aripiprazole Orally disintegrating tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosiqing
Description: Aripiprazole Orally disintegrating tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosiqing
Description: Aripiprazole Orally disintegrating tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abilify
Description: Aripiprazol orodispersible tablets 10mg
Study: NCT03176901

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction
Description: This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Enhancement Program
Description: This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
Study: NCT04564521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: Intravenous nitroglycerin (0.5mcg/kg/min) is infused after the induction of general anesthesia and during intra-arterial chemotherapy to reduce the cardio-respiratory side effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Intravenous normal saline is infused after the induction of general anesthesia and during intra-arterial chemotherapy as an active comparator.
Study: NCT04735783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo breakfast
Description: Participants will consume a very low-energy, placebo breakfast meal, but will be unaware of its near complete absence of energy until the end of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Typical whole-food breakfast
Description: Participants will consume a typical whole-food breakfast meal, equating to 20% of estimated energy requirements.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water-only control
Description: Participants will consume a volume of plain water to match the water content of the very low-energy placebo breakfast and the typical whole-food breakfast.
Study: NCT01542554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic index diet
Description: Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual diabetic diet
Description: Diabetic subjects will be given dietary advice without mention about glycaemic index
Study: NCT00706771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride
Description: 0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
Study: NCT05611541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet therapy, Progressive Muscle Relaxation training, Progressive Muscle Relaxation group
Description: The group that received Progressive Muscle Relaxation training and applied progressive muscle relaxation for 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The group who received diet therapy and practiced their daily activities.
Description: The group who received diet therapy and practiced their daily activities.
Study: NCT04127071

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Needle Aspiration Procedure
Description: The intervention under investigation utilizes an ultrasound-guided needle to less invasively drain an abscess.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Incision and Drainage (I&D)
Description: The current standard procedure to drain an abscess of purulent material.
Study: NCT02166476

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem-Vaborbactam
Description: Meropenem-vaborbactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-Tazobactam
Description: Piperacillin-tazobactam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT03067363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MOR107
Description: MOR107 solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection manufactured to match MOR107 solution for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection manufactured to match MOR107 solution for injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low sodium diet
Description: Diet designed to restrict sodium intake to 40 mmol/day
Study: NCT02250768

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 2ng/ml of GM-CSF supplemented into culture media
Study: NCT02820064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: duodenal biopsy during gastroduodenal endoscopy
Description: Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
Study: NCT04111900

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep/Circadian Friendly
Description: This intervention attempts to improve sleep and prevent circadian rhythm dysregulation among patients admitted to the medical intensive care unit (MICU). Patients within his arm will be asked to try to keep their TV off and limit their telephone use from 10pm-7am, as well as limit the amount of visitors in their room as much as possible between those hours. Patients will also be offered ear plugs and eye masks if they wish to use at night to aid in helping them sleep, if deemed medically safe to do so. Additionally nurses will be asked to bathe patients either before 10pm or after 7am, to limit their conversations in the patient's room at night, and try as much as possible to limit blood draws and waking patients during those hours as is medically safe. Nurses will also be instructed to lower the blinds in the room at 10 pm and raise them up at 7am to help with patients sleep/wake cycle.
Study: NCT04843410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand-foot exercise
Description: The experimental group will be taught a regular exercise program for 15 minutes twice a day. The sensory exercise ball required for exercise will be given to the patients by the researcher. In addition, visual training material will be provided for the exercise program so that the patient can repeat the training at any time to ensure the permanence of the patient education. The standard care protocol of the clinic will be applied to the control group.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: The routine care
Description: Education about chemotherapy-associated peripheral neuropathy risk factors, why it develops and its management
Study: NCT01606319

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 15 mg/kg every 6 hours as needed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 9.4 mg/kg every 6 hours as needed
Study: NCT04513977

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geriatric Oncology Supportive Clinic
Description: Patients will undergo Comprehensive Geriatric Assessment with subsequent tailored intervention based on deficits identified. Comprehensive palliative assessment for any symptom burden and symptommatic treatment will be done as well.
Study: NCT02603705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone extended-release
Study: NCT00867100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 700 mg IV
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 350 mg SC
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 140 mg SC
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study: NCT06120647

Intervention type: DIETARY_SUPPLEMENT
Intervention: Essential amino acids (EAA)
Description: intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Intervention type: DIETARY_SUPPLEMENT
Intervention: Essential amino acids (EAA)
Description: intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Intervention type: DIETARY_SUPPLEMENT
Intervention: Essential amino acids (EAA)
Description: intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Intervention type: DIETARY_SUPPLEMENT
Intervention: Essential amino acids (EAA)
Description: intake of 240 mg EAA per kg lean body mass after a resistance exercise session
Study: NCT02585297

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention

Intervention type: OTHER
Intervention: no intervention